network member

Washington, D.C.

About Network Member

Currently Enrolling

HCRN-GU22-587

Advanced Renal Cell Cancer Combination ImmunoThErapy Clinical Trial (ARCITECT)

Cancer areas:Kidney

Beth Israel Deaconess Medical Center

Columbia University Irving Medical Center

Dana-Farber Cancer Institute

Georgetown Lombardi Comprehensive Cancer Center

Indiana University Melvin and Bren Simon Comprehensive Cancer Center

John Theurer Cancer Center at Hackensack Meridian Health

Moores Cancer Center at UC San Diego Health

Penn Medicine Abramson Cancer Center

The Ohio State University

UT Southwestern Harold C. Simmons Comprehensive Cancer Center

Weill Cornell Medicine

Winship Cancer Institute of Emory University

Yale Cancer Center

See clinicaltrials.gov

Currently Enrolling

TBCRC046

A Phase II Trial of Avelumab or Hydroxychloroquine with or without Palbociclib to Eliminate Dormant Breast Cancer (“PALAVY”)

Angela DeMichele

Cancer areas:Breast

Dana-Farber Cancer Institute

Fred Hutchinson Cancer Research Center

Georgetown Lombardi Comprehensive Cancer Center

Indiana University Melvin and Bren Simon Comprehensive Cancer Center

Penn Medicine Abramson Cancer Center

The University of Chicago Medicine Comprehensive Cancer Center

Vanderbilt-Ingram Cancer Center

See clinicaltrials.gov

Currently Enrolling

TBCRC047

Innovative Combination Immunotherapy for Metastatic Triple Negative Breast Cancer (TNBC): A Multicenter, Multi-Arm Translational Breast Cancer Research Consortium Study

Hope Rugo

Cancer areas:Breast

Dana-Farber Cancer Institute

Duke Cancer Institute

Georgetown Lombardi Comprehensive Cancer Center

Mayo Clinic

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

The University of Chicago Medicine Comprehensive Cancer Center

UC San Francisco

University of Alabama at Birmingham Comprehensive Cancer Center

University of North Carolina Lineberger Comprehensive Cancer Center

Vanderbilt-Ingram Cancer Center

See clinicaltrials.gov

Enrollment Closed

HCRN-BRE18-334

A Phase II circulating tumor DNA enriched, genomically directed post-neoadjuvant trial for patients with residual triple negative breast cancer (PERSEVERE)

Bryan P. Schneider

Cancer areas:Breast

Advocate Aurora Research Institute (Illinois)

Aurora Health Care

Froedtert & the Medical College of Wisconsin

Georgetown Lombardi Comprehensive Cancer Center

Indiana University Melvin and Bren Simon Comprehensive Cancer Center

Miami Cancer Institute at Baptist Health, Inc.

Novant Health Oncology Specialists

The University of Chicago Medicine Comprehensive Cancer Center

University of Alabama at Birmingham Comprehensive Cancer Center

University of Wisconsin Carbone Cancer Center

UT Health San Antonio MD Anderson Cancer Center

See clinicaltrials.gov

Enrollment Closed

HCRN-GU16-260

Phase II study of front line therapy with nivolumab and salvage nivolumab + ipilimumab in patients with advanced renal cell carcinoma

Michael B. Atkins

Cancer areas:Kidney

Beth Israel Deaconess Medical Center

Cleveland Clinic Cancer Center

Columbia University Irving Medical Center

Fox Chase Cancer Center

Georgetown Lombardi Comprehensive Cancer Center

Penn Medicine Abramson Cancer Center

Robert H. Lurie Comprehensive Cancer Center of Northwestern University

University of Illinois Cancer Center

UT Southwestern Harold C. Simmons Comprehensive Cancer Center

Winship Cancer Institute of Emory University

Yale Cancer Center

See clinicaltrials.gov

Enrollment Closed

HCRN-MEL17-309

Phase II single-arm multi-center study of adjuvant ipilimumab in combination with nivolumab in subjects with high-risk ocular melanoma

Suthee Rapisuwon

Cancer areas:Melanoma

Columbia University Irving Medical Center

Georgetown Lombardi Comprehensive Cancer Center

MD Anderson Cancer Center

Robert H. Lurie Comprehensive Cancer Center of Northwestern University

Siteman Cancer Center at Barnes-Jewish Hospital and Washington University School of Medicine

UC San Francisco

See clinicaltrials.gov

Study Completed

TBCRC044

A Randomized Phase II Study of Pembrolizumab, an Anti-PD (Programmed Cell Death)-1 Antibody, in Combination With Carboplatin Compared to Carboplatin Alone in Breast Cancer Patients With Chest Wall Disease

Hope Rugo

Cancer areas:Breast

Dana-Farber Cancer Institute

Georgetown Lombardi Comprehensive Cancer Center

Indiana University Melvin and Bren Simon Comprehensive Cancer Center

The University of Chicago Medicine Comprehensive Cancer Center

UC San Francisco

UPMC Hillman Cancer Center

Vanderbilt-Ingram Cancer Center

See clinicaltrials.gov